AAV Genome Optimization

In the rapidly growing field of gene therapy, Adeno-Associated Virus (AAV) vectors have emerged as a leading platform for delivering genetic material into cells. While much attention is often given to AAV capsids — the protein shells that determine targeting and delivery — the AAV genome inside the capsid is just as critical. The design of the AAV genome directly impacts expression, safety, and therapeutic outcomes.

The AAV genome is a single-stranded DNA molecule, typically around 4.7 kilobases (kb) in length — a limitation defined by the virus’s natural packaging capacity. Unlike wild-type AAV, which contains viral genes (Rep and Cap), recombinant AAV used in gene therapy replaces these genes with a therapeutic expression cassette flanked by Inverted Terminal Repeats (ITRs).  Self-Complementary AAV (scAAV) is engineered to bypass the rate-limiting second-strand synthesis by packaging a genome that folds back on itself, forming double-stranded DNA. While this improves expression kinetics, scAAV has a reduced packaging capacity (~2.4 kb).

A poorly designed or unstable AAV genome can lead to low productivity, high impurity levels, or reduced therapeutic efficacy. Understanding how genome structure influences AAV manufacturing and quality control is essential for both research and clinical applications.

  • Genome Heterogeneity:
    Incorrectly packaged or recombined genomes lead to batch heterogeneity, affecting potency and reproducibility.

  • Impurity Levels:
    Poor genome design can increase host cell DNA, plasmid backbone sequences, or truncated genomes in the final product — all critical impurity concerns for regulatory compliance.

  • Production Yield:
    Suboptimal genome structure reduces packaging efficiency, leading to lower vector yields and increased production costs.

  • Therapeutic Efficacy:
    AAV vectors carrying incomplete, unstable, or heterogeneous genomes may fail to deliver consistent gene expression in vivo.

Key cis-elements in AAV vector genome

 
  • Inverted Terminal Repeats (ITRs): ITRs are short DNA sequences located at both ends of the AAV genome, essential for AAV replication, packaging into capsids, and integration into the host cell genome. They serve as the starting point for viral DNA replication and guide the encapsidation of the viral genome. The wild-type AAV2 ITR is 145 nucleotides long but is relatively unstable. A commonly used variant is the 130 bp ITR (ITR130), which omits the 15 nucleotides from the 3′ OH end. Additionally, an 11 bp deletion in the C-domain (ITR119) is often seen in AAV plasmids. These mutated ITRs are repaired during AAV replication, resulting in final vectors containing wild-type ITRs. It’s crucial to ensure that your ITRs are functional before initiating AAV packaging.
  • Promoter: The promoter is a regulatory DNA sequence that initiates transcription of the gene of interest, dictating the timing and location of gene expression in target cells. Choosing the appropriate promoter enables researchers to achieve desired expression levels and specificity. Commonly used promoters like CMV, CAG, uBC, and EF1a drive strong, consistent expression across various cell types. Tissue-specific promoters allow for precise control of gene expression in targeted biological contexts.
  • Enhancers: Incorporating enhancers into AAV vectors can significantly boost gene expression.  Enhancers, such as WPRE or WPRE3, can increase the activity of promoters in a tissue-specific or inducible manner, allowing for precise control of gene expression. 
  • Intron. Introns can enhance transcript levels by affecting transcription rates, nuclear export, and transcript stability. They also contribute to the efficiency of mRNA translation, making them valuable additions to AAV vectors.
  • Gene of Interest (Transgene): The gene of interest is the DNA sequence encoding the desired protein or RNA to be introduced into target cells. This can include therapeutic genes, reporter genes, or functional genetic elements such as sgRNA, shRNA, or lncRNA. It’s critical to ensure that the size of the transgene is compatible with packaging capacity of AAV vectors, which typically accommodate payloads of around 4.7 kb or slightly less.
  • Polyadenylation (PolyA) Signal: The PolyA signal is a sequence that signals the termination of transcription and facilitates the addition of a polyadenine tail to the RNA molecule. This step is crucial for generating mature mRNA and ensuring proper gene expression.
  • Other Regulatory Elements: These elements are responsible for fine-tuning the level and specificity of gene expression. Several additional regulatory elements can be incorporated to fine-tune gene expression:
    • Insulator Sequences: Prevent the spread of heterochromatin, ensuring that the inserted gene is not silenced by neighboring DNA regions.
    • MicroRNA Target Sites: Can be added to the 3′ UTR to post-transcriptionally regulate gene expression, allowing for cell-specific silencing of the therapeutic gene.

AAV Genome Optimization

AAVnerGene offers specialized AAV genome optimization services, designed to enhance the expression and functionality of your gene of interest (GOI) and reduce the impurities within AAV vectors, paving the way for successful gene therapy results. Those services includes:

  • Genome Size Optimization:  Optimize the size of your GOI and regulatory elements to fit within the AAV packaging limit (~4.7 kb). Use strategies such as small intron, minimal promoter, and compact polyadenylation signals to reduce vector size. Employ split gene or dual vector systems for larger transgenes that exceed the AAV packaging capacity.
  • Cis-Element Optimization:  Test and compare different regulatory elements (ITR, promoter, enhancer, intron, PolyA) to achieve optimal transgene expression levels and specificity. Comparison of large number of promoters and enhancers with barcode-seq technology.
  • Codon Optimization: Refine the coding sequence of your GOI to enhance expression in the target cell type.
  • Genomic Optimization: Refine the AAV genomic sequence to reduce partial or incomplete genomes and improve AAV quality. 
  • Backbone optimization: Refine the backbone sequences and reduce the backbone related impurities(such as resistant markers and bacterial origins) in final AAV products.
  • Expression Validation: Assess transgene expression and biodistribution at the DNA, RNA, and protein levels using techniques such as qPCR, RNA sequencing, and functional assays.

AAV Genome Size Optimization Services

AAV genome size control is a crucial aspect of AAV vector design and production, as it directly impacts packaging efficiency, vector stability, and transgene expression. The AAV packaging capacity is limited to approximately 4.7 kilobases (kb), making it essential to carefully optimize the size of the transgene and regulatory elements to ensure successful gene delivery. 

At AAVnerGene, we specialize in optimizing AAV genome size to enhance the efficiency, stability, and functionality of your gene therapy vectors. Our comprehensive services are designed to address the challenges associated with packaging large genes into AAV capsids, ensuring optimal gene delivery and expression.

  • Minimal AAV Genome Size: We specialize in refining AAV genome size to maximize packaging efficiency while preserving the integrity of your therapeutic genes. By eliminating non-essential elements and optimizing critical components, we ensure your AAV vectors are compact, stable, and highly efficient. Our approach includes:

    • Mini-Promoters: Utilizing compact promoters like miniCMV to drive gene expression without compromising space.

    • Small Enhancers: Incorporating efficient enhancers such as the CMV enhancer and WPRE3 to boost expression levels in a minimal footprint.
    • Small Introns: Employing streamlined introns like the SV40 intron to enhance splicing efficiency while minimizing size.
    • Small Transgenes: Using compact versions of transgenes, such as miniGFP2, to reduce overall genome size.
    • Small PolyA Signals: Integrating concise polyadenylation signals to ensure proper transcript termination without excess sequence.

  • Dual AAV Vector Strategies: For genes that exceed the packaging capacity of a single AAV vector, we offer advanced dual AAV vector solutions. These strategies include:

    • Dual Functional AAV Vectors: Splitting large genes into two functional fragments, each delivered by separate vectors, which combine to produce a full-length protein.

    • Overlapping Dual AAV Vectors: Utilizing overlapping sequences to facilitate the seamless joining of two gene fragments.

    • Trans-Splicing Dual AAV Vectors: Leveraging ITR concatemerization and splice sites to assemble distinct gene fragments into a complete transcript.

    • Hybrid Dual AAV Vectors: Combining overlapping and trans-splicing approaches for enhanced precision and reliability.

Cis-Element Optimization Services

Cis-element optimization is essential for achieving high levels of transgene expression in target cells or tissues while reducing off-target effects. At AAVnerGene, we provide comprehensive Cis-Element Optimization Services to help you maximize the efficiency and specificity of your AAV vectors.

Our services include:

  • Combining Different Elements: We expertly design and assemble various cis-elements to create optimized constructs tailored to your specific needs.

  • Selecting the Most Efficient Elements: Through rigorous screening, we identify the most effective promoters, enhancers, and other regulatory elements to enhance transgene expression.

  • Evaluating Constructs In Vitro and In Vivo: We conduct thorough testing in both cellular and animal models to ensure optimal performance and functionality of your AAV vectors.

Promoters and enhancers are critical cis-elements that significantly influence AAV transduction efficiency and target specificity. At AAVnerGene, we leverage advanced Barcode-Seq technology to efficiently evaluate and optimize a large number of promoters and enhancers. Our Barcode-Seq-based platform enables:

  • High-Throughput Screening: Rapid and simultaneous assessment of multiple promoters and enhancers to identify the most effective combinations.

  • Precision and Accuracy: Quantifiable evaluation of transgene expression levels and specificity in target cells or tissues.

  • Data-Driven Optimization: Comprehensive analysis to select the optimal cis-elements for your specific gene therapy applications.

GOI Codon Optimization Services

At AAVnerGene, we offer GOI Codon Optimization Services to help researchers maximize the expression and functionality of their gene of interest (GOI) within AAV vectors. Codon optimization is a critical step in ensuring efficient translation and high-level protein expression in target cells, which is essential for the success of gene therapy and research applications.

  • Custom Codon Optimization: Refine the coding sequence of your GOI to match the codon usage preferences of your target cell type or organism.
  • Host-Specific Optimization: Tailor codon usage to the specific host system, whether it’s human, mouse, rat, or other model organisms.
  • GC Content Adjustment: Optimize the GC content of your GOI to improve mRNA stability and expression levels.
  • Rare Codon Elimination:  Identify and replace rare codons that may slow down translation or cause errors.
  • Integration with Regulatory Elements: Combine codon optimization with optimized promoters, enhancers, and polyadenylation signals for a fully optimized expression cassette.

AAV Genome Optimization: Vector Quality

At AAVnerGene, we offer Genome Sequence Optimization Services to refine the AAV genomic sequence, ensuring the production of high-quality, full-length AAV vectors. Partial genomes or other incomplete AAV genomes can compromise the efficiency and functionality of AAV vectors, making genomic optimization a critical step in AAV production. Our services are designed to minimize partial genomes and enhance the overall quality of your AAV preparations.

  • Reduction of Partial Genomes: Optimize the AAV genomic sequence to minimize the formation of incomplete or fragmented genomes during packaging. Increases the proportion of full-length genomes in the final AAV product. Enhances transduction efficiency and transgene expression.
  • Sequence Refinement: Refine the AAV genome to improve stability and packaging efficiency. Reduces the risk of rearrangements or deletions during vector production. Ensures the integrity of the transgene and regulatory elements.

AAV Backbone Optimization Services

The presence of residual helper plasmid genomes from the production process can contribute to genomic impurities. This occurs if the helper plasmid is not fully removed during downstream purification or if its sequences are inadvertently packaged into AAV vectors. Plasmid backbone-related impurities, which include residual backbone sequences not part of the intended transgene expression cassette, can compromise the safety and efficacy of gene therapy products.

  • AAVtri systems, the primary contaminants stem from the backbone of the pAAV-GOI plasmid, while sequences from the trans plasmid are packaged at much lower levels.
  • AAVone system incorporates an oversized 13 kb backbone, which significantly reduces bacterial-related impurities and enhances the purity of the final AAV product. This innovative approach minimizes unwanted backbone sequences, ensuring higher-quality gene therapy vectors.